Drugs similar to the original (biosimilars) for the treatment of diseases such as cancer or rheumatoid arthritis have allowed access to a larger number of people who could not be treated earlier because of the high costs.
The industry develops treatments similar to those of reference and this is of great importance for patients, raised European chemists who work in the development of health products. In addition, the original (innovative) drugs reduced the millionaire prices they had for sales due to competition generated by similar biosimilars.
Eduardo Cioppi, regional director and Luisa Amoedo, director of a modern factory in León, northern Spain, spoke extensively about the process of arriving at a biosimilar drug to the original molecule.
More Access For Spanish pharmaceutical leaders, biosimilars contribute to a greater number of patients with access to quality medicines. However, there are obstacles in the countries where these treatments are in use, they insist.
To address the barriers to access to populations of high-cost disease patients, we work with key groups such as physicians to raise awareness of what is happening in the market and the benefits of access.
Experience The main medicines of the company mAbxience and the consortium that integrates it, have had a satisfactory experience in recent years. Its main products are for cancer and rheumatoid arthritis. These treatments similar to the original molecule are available in 15 countries in Latin America, Europe and the United States. Currently working for legal procedures, says Eduardo Cioppi, commercial director of the company Latam.
These drugs that give greater access to patients with cancer and rheumatoid arthritis have clinical experience in 14,000 people in Latin America, say MAxience leaders and affiliated companies in Spain.
Leading products have forced their presence to practice clearer rules for the benefit of companies and patients themselves. Its health records are present in 15 countries, including the Dominican Republic, Argentina, Paraguay, Guatemala, Mexico, Nicaragua and Venezuela.
Leaders Their medicines Rituximab and Bevacizumab are its main products and four other drugs are in preparation, say Amoedo and Cioppi. Access and high quality therapeutic solutions are sought for high cost diseases.
These products are compared with the innovative medicine and should give the same answers.
The difference between the biosimilars and the innovators is that the latter are cultivated in living cells, although the biosimilar must demonstrate their studies. It can not be more or less efficient than the brand name drug. Biosimilar drugs should behave as such, even in the side effects that innovators may have.
Around the subject they face ethical concepts that involve the interests of companies.
However, the development of biosimilars, which have been expanding since the release of patents, has generated a kind of "war" on the market, and in many cases patients are trapped between a disease and a host of contradictory information. .
The managers of the consortium of Spanish companies are aware of the discussions that occur in Latin America, from the entry of biosimilars. In these countries they have always been and without competition, innovative medicines, says Cioppi.
A model Luisa Amoedo, a long-time chemist who runs the drug and product factory in León, has shown to Latin American journalists, strict quality controls for injectable drugs. Polivizumab, a drug to reduce deaths in respiratory virus neonates to zero, is in development. The drug would be ready in six years, with the goal of impacting child deaths.